Dräger released a strong set of estimate-beating preliminary Q3 23 numbers, sending the stock ~10% higher (at pixel time). While the growth was led by the safety segment, we were pleasantly surprised by the medical division’s order intake which returned to strong growth as well as the good cost control/management. Following the Q3 update, we expect a high-single digit to low double-digit upgrade to our FY23 estimates.
